As the Dangote Petroleum Refinery, Africa’s largest single-train refining complex, begins operations, its potential impact is being debated far beyond the energy sector.
For two seasoned pharmaceutical supply chain professionals, the project could represent the industrial backbone that Nigeria has long needed to achieve pharmaceutical independence.
Yusuf Olanlokun, a pharmacist with a decade of experience across public and private health systems and currently an MBA candidate at the University of California, Berkeley, and Moyosore Taiwo, a pharmacist with more than 14 years’ experience in global health and pharmaceutical manufacturing with an MBA from the University of Toronto, argue that the refinery’s integrated petrochemical design may finally close the missing link in Nigeria’s drug value chain.
Both, however, caution that without deliberate policy action and disciplined execution, the opportunity could be wasted.
From Import Dependence to Industrial Potential
For decades, Nigeria’s pharmaceutical sector has been marked by heavy import dependence. Around three-quarters of all medicines consumed in the country are sourced from abroad. Domestic companies have largely been confined to secondary manufacturing—formulating imported active pharmaceutical ingredients (APIs) into finished dosage forms.
This dependence has left Nigeria exposed to recurring shortages, especially when global logistics are disrupted, as during the COVID-19 pandemic.
The system also creates an opening for substandard and falsified medicines to circulate, while draining an estimated $1.1 billion annually from scarce foreign exchange reserves. The effects are felt most acutely by households. According to Olanlokun, “Currency instability is one of the biggest deterrents to investment in local API plants. When the Naira is volatile, the business case for large-scale chemical production evaporates.”
The $20 billion Dangote Refinery is expected to change this equation. With a capacity of 650,000 barrels per day, the facility is designed not only to reduce imports of refined petroleum—which historically accounted for 15 to 20 percent of Nigeria’s entire import bill—but also to anchor downstream petrochemicals. By substituting petroleum product imports, the refinery will ease pressure on foreign exchange reserves and provide greater stability for the Naira.
Analysts at Proshare project that GDP growth could rise to 4.15 percent with the refinery fully operational, compared with 3.34 percent without it.
Taiwo connects the dots directly: “The refinery is not just an oil project. By stabilizing FX, it creates the certainty required for investors to fund upstream pharmaceutical production. That’s the missing piece we’ve been waiting for.”
Equally important is the refinery’s petrochemical integration. Alongside fuels, it is designed to produce aromatics and olefins—the chemical building blocks required for complex pharmaceutical synthesis.
This matters because true self-reliance goes beyond importing APIs and mixing them locally. It requires the domestic production of APIs from Key Starting Materials (KSMs) and Drug Intermediates (DIs), which themselves come from petrochemicals.
Without this step, Nigeria risks replicating India’s experience. Despite being the “pharmacy of the world” in generics, India still imports roughly 70 percent of its KSMs and intermediates from China. Taiwo warns, “Nigeria must avoid that trap.
The opportunity now is to build full backward integration.” If successful, the refinery could shorten lead times, reduce cost exposure, and minimize inventory risks across the pharmaceutical supply chain.
Policy, Regulation, and the Execution Challenge
The refinery’s industrial potential alone will not deliver transformation. Olanlokun and Taiwo argue that policy alignment is critical across three fronts: feedstock security, demand anchoring, and regulatory credibility.
The first is feedstock security. International oil companies have often preferred exporting crude for U.S. dollars rather than meeting domestic commitments. If the Domestic Crude Supply Obligation (DCSO) is not enforced rigorously, API investors could face unpredictable input supplies. “Without guaranteed feedstock, pharmaceutical clusters will collapse before they begin,” Olanlokun noted.
The second is demand anchoring. Nigeria’s $1.1 billion annual pharmaceutical import bill represents a ready demand pool for substitution. Yet tariff exemptions on API raw materials, while helpful, are insufficient without volume commitments.
The experts recommend framework contracts with guaranteed purchases, public procurement mandates for locally manufactured APIs, and long-term offtake agreements for essential medicines like antimalarials. “Investors need assurance of scale,” Taiwo explained. “Otherwise, Nigerian firms cannot hope to match the economies of India or China.”
The third is regulatory credibility. Strengthening NAFDAC’s capacity to enforce Good Manufacturing Practice (GMP) standards is essential. Without GMP-compliant APIs, local producers will struggle to gain trust at home, let alone export under the African Continental Free Trade Area (AfCFTA).
“Regulation is the bridge between ambition and acceptance,” Taiwo said. “It will decide whether Nigeria becomes a regional hub or remains a dependent market.”
The potential benefits extend far beyond pharmaceuticals. Local manufacturing would create high-skill jobs in chemistry, engineering, and logistics. It would attract research and development partnerships, drive regional trade, and improve public health outcomes by stabilizing drug prices and reducing counterfeit prevalence.
The World Bank has long emphasized that investments in health manufacturing yield broader economic multipliers through productivity gains and healthcare cost savings.
Yet the obstacles are real. Energy costs remain high across Nigeria, even with the Dangote complex’s dedicated 435MW power plant. Distribution inefficiencies within the country add up to 30 percent to medicine retail prices. And the country’s record on industrial execution is mixed: from steel to fertilizers, ambitious projects have often fallen short due to policy inconsistency and governance gaps. Taiwo was blunt: “The risk isn’t in the vision—it’s in the execution.”
A Regional Hub or a Missed Opportunity?
Global examples show what is at stake. India leveraged petrochemical clusters in Gujarat and Hyderabad in the 1980s to build its pharmaceutical dominance but left itself reliant on Chinese intermediates.
China pursued full vertical integration from refining to APIs, securing a commanding position in global supply chains. Brazil, meanwhile, faltered because inconsistent procurement policies prevented its pharmaceutical industry from scaling, leaving it dependent during health crises.
Nigeria now stands at a crossroads. The Dangote Refinery offers the structural foundation to shift from dependency to resilience. If policies are enforced, demand commitments secured, and regulation strengthened, the country could become West Africa’s pharmaceutical hub. If not, it risks remaining trapped in the same cycle of import dependence and price volatility.
For Olanlokun and Taiwo, the stakes are personal as well as professional. “This is about the health of 200 million Nigerians,” Olanlokun said. “Access to quality medicines should not depend on global supply shocks or exchange rate swings. The refinery gives us a platform. What remains is whether we have the discipline and political will to seize it.”
